Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation
Zhiqing Liu, Haiying Chen, Pingyuan Wang, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 10, pp. 5242-5256
Open Access | Times Cited: 70

Showing 26-50 of 70 citing articles:

4-Methyl-1,2,3-Triazoles as N-Acetyl-Lysine Mimics Afford Potent BET Bromodomain Inhibitors with Improved Selectivity
Huarui Cui, Angela S. Carlson, Mary A. Schleiff, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 14, pp. 10497-10511
Open Access | Times Cited: 29
Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases
Yi Li, Jianping Chen, Andrew A. Bolinger, et al.
Inflammatory Bowel Diseases (2021) Vol. 27, Iss. Supplement_2, pp. S38-S62
Open Access | Times Cited: 29
Targeting BET Bromodomains in Cancer
Patrick Trojer
Annual Review of Cancer Biology (2022) Vol. 6, Iss. 1, pp. 313-336
Open Access | Times Cited: 19
Multi-Water Bridges Enable Design of BET BD1-Selective Inhibitors for Pancreatic Cancer Therapy
Xuetao Chen, Wenjing Kang, Tingting Wu, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
SMARCA4 regulates inducible BRD4 genomic redistribution coupling intrinsic immunity and plasticity in epithelial injury-repair
Xiaofang Xu, Allan R. Brasier
Nucleic Acids Research (2025) Vol. 53, Iss. 6
Open Access
Orally Bioavailable BRD4 BD1 Inhibitor ZL0516 Effectively Suppresses Colonic Inflammation in Animal Models of Inflammatory Bowel Disease
Zonghui Ma, Steven McAninch, Zhiqing Liu, et al.
ACS Pharmacology & Translational Science (2025) Vol. 8, Iss. 4, pp. 1152-1167
Closed Access
A Bromodomain-Containing Protein 4 (BRD4) Inhibitor Suppresses Angiogenesis by Regulating AP-1 Expression
Zijun Zhou, Xiaoming Li, Zhiqing Liu, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 29
Discovery and characterization of cyclic peptides selective for the C-terminal bromodomains of BET family proteins
Charlotte Franck, Karishma Patel, Louise J. Walport, et al.
Structure (2023) Vol. 31, Iss. 8, pp. 912-923.e4
Open Access | Times Cited: 9
Cooperative interaction of interferon regulatory factor -1 and bromodomain—containing protein 4 on RNA polymerase activation for intrinsic innate immunity
Xiaofang Xu, Dianhua Qiao, Allan R. Brasier
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Discovery of the First BRD4 Second Bromodomain (BD2)-Selective Inhibitors
Junhua Li, Qingqing Hu, Run Zhu, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 3
Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors
Helen Aylott, Stephen J. Atkinson, Paul Bamborough, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 6, pp. 3249-3281
Closed Access | Times Cited: 23
Structure-Based Discovery and Optimization of Furo[3,2-c]pyridin-4(5H)-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors
Junhua Li, Cheng Zhang, Hongrui Xu, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 7, pp. 5760-5799
Closed Access | Times Cited: 15
Accounting for Solvation Correlation Effects on the Thermodynamics of Water Networks in Protein Cavities
Emília P. Barros, Benjamin Ries, Candide Champion, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 6, pp. 1794-1805
Open Access | Times Cited: 8
Targeting the epigenetic reader “BET” as a therapeutic strategy for cancer
Abhishek Wahi, Namish Manchanda, Priti Jain, et al.
Bioorganic Chemistry (2023) Vol. 140, pp. 106833-106833
Closed Access | Times Cited: 7
Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis
Xuetao Chen, Tingting Wu, Zhiyan Du, et al.
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116080-116080
Closed Access | Times Cited: 7
Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins
Yuantao Fu, Yanzhi Zhang, Haiying Sun
European Journal of Medicinal Chemistry (2021) Vol. 226, pp. 113853-113853
Closed Access | Times Cited: 17
Selective Inhibition of Bromodomain-Containing Protein 4 Reduces Myofibroblast Transdifferentiation and Pulmonary Fibrosis
Ksenija Bernau, Melissa Skibba, Jonathan P. Leet, et al.
Frontiers in Molecular Medicine (2022) Vol. 2
Open Access | Times Cited: 11
Elucidating the structural and conformational preferences of bioactive chromone and its monohydrate through advanced rotational spectroscopy
Junhua Chen, Min Zhang, Junlin Lan, et al.
The Journal of Chemical Physics (2024) Vol. 160, Iss. 17
Closed Access | Times Cited: 2
Targeting lysine acetylation readers and writers
Ming‐Ming Zhou, Philip A. Cole
Nature Reviews Drug Discovery (2024)
Closed Access | Times Cited: 2
Discovery of Dual CDK6/BRD4 Inhibitor Inducing Apoptosis and Increasing the Sensitivity of Ferroptosis in Triple-Negative Breast Cancer
Yonglei Zhang, Long Zheng, Liangliang Ma, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 23, pp. 21186-21207
Closed Access | Times Cited: 2
Discovery of 1H-Imidazo[4,5-b]pyridine Derivatives as Potent and Selective BET Inhibitors for the Management of Neuropathic Pain
Xuetao Chen, Danyan Cao, Chihong Liu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 8725-8744
Closed Access | Times Cited: 6
Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe
Erin K. Bradley, Lucia Fusani, Chun‐wa Chung, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 23, pp. 15728-15749
Open Access | Times Cited: 6
Bromodomain Containing Protein 4 (BRD4) Regulates Expression of its Interacting Coactivators in the Innate Response to Respiratory Syncytial Virus
Xiaofang Xu, Morgan Mann, Dianhua Qiao, et al.
Frontiers in Molecular Biosciences (2021) Vol. 8
Open Access | Times Cited: 12
Discovery of 2-((2-methylbenzyl)thio)-6-oxo-4-(3,4,5-trimethoxyphenyl)-1,6-dihydropyrimidine-5-carbonitrile as a novel and effective bromodomain and extra-terminal (BET) inhibitor for the treatment of sepsis
Xuetao Chen, Fanying Meng, Jingtian Zhang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114423-114423
Closed Access | Times Cited: 8
Rational design, synthesis and biological evaluation of benzo[d]isoxazole derivatives as potent BET bivalent inhibitors for potential treatment of prostate cancer
Junhua Li, Run Zhu, Xiaoxi Zhuang, et al.
Bioorganic Chemistry (2023) Vol. 135, pp. 106495-106495
Closed Access | Times Cited: 4

Scroll to top